http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 09:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/Press+Releases/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592 http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html <div class="xn-content"> <p><i><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> Scalable Platform for <span>Integrated Research</span> and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practices</i></p><p><span class="legendSpanClass"><location value="LU/us.oh.colbus" idsrc="xmltag.org" >Columbus, Ohio</location> and <location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health</span> today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in <location value="LC/us" idsrc="xmltag.org" >the United States</location> evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors. The trial uses <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700506-1&amp;h=399277428&amp;u=https%3A%2F%2Fwww.paradigmhealth.ai%2Fsolutions%2Fscalable-platform-for-integrated-research-evidence&amp;a=Paradigm+Health%27s+SPIRE+model" target="_blank" rel="nofollow"><span value="ACORN:5020484467" idsrc="xmltag.org" >Paradigm Health's</span> SPIRE model</a> http://www.streetinsider.com/PRNewswire/Paradigm+Health+Implements+New+Clinical+Trial+Solution+to+Support+Observational+Study+Presented+at+ASCO/26580319.html Mon, 01 Jun 2026 09:00:00 -0400 A.06822034 A.21794726 A.40306239 A.50204844 A.50214950 A.50216726 FCS O.00182009 O.20026344 O.20087471 O.21612337 O.23870703 O.50936592